Soluble β-amyloid (Aβ) oligomers impair synaptic plasticity and cause synaptic loss associated with Alzheimer's disease (AD). We report that murine PirB (paired immunoglobulin-like receptor B) and its human ortholog LilrB2 (leukocyte immunoglobulin-like receptor B2), present in human brain, are receptors for Aβ oligomers, with nanomolar affinity. The first two extracellular immunoglobulin (Ig) domains of PirB and LilrB2 mediate this interaction, leading to enhanced cofilin signaling, also seen in human AD brains. In mice, the deleterious effect of Aβ oligomers on hippocampal long-term potentiation required PirB, and in a transgenic model of AD, PirB not only contributed to memory deficits present in adult mice, but also mediated loss of synaptic plasticity in juvenile visual cortex. These findings imply that LilrB2 contributes to human AD neuropathology and suggest therapeutic uses of blocking LilrB2 function.
protein (APPswe) and presenilin 1 (PSEN1ΔE9) are expressed (15, 16) : Ocular dominance plasticity (ODP) during the critical period of development in visual cortex [postnatal day 22 (P22) to P32] is defective (17) . This observation directly contrasts with mice lacking PirB (paired immunoglobulin-like receptor B), in which ODP is enhanced during the critical period and in adults (18) . PirB, a receptor originally thought to function exclusively in the immune system (19) , is now also known to be expressed by neurons, present in neuronal growth cones, and associated with synapses (18, 20) . Thus, it is possible that Aβ acts through PirB to diminish ODP in APP/PS1 mice.
To determine whether PirB can act as a receptor for soluble Aβ oligomers, we prepared biotinylated synthetic human Aβ (Aβ42) peptides either without (mono-Aβ42) or with oligomerization (oligo-Aβ42; consists primarily of high-n oligomers) (Fig. 1, A and B, and fig. S1A) (12, 21, 22) . We then measured binding of Aβ42 peptides to human embryonic kidney (HEK) 293 cells that expressed mouse PirB (PirB-IRES-EGFP) or control vector (IRES-EGFP). Relative to monomeric Aβ42, oligomerized Aβ42 peptides bound to PirBexpressing cells about 6 times as much (Fig. 1, A to D) . Oligo-Aβ42 was consistently associated with PirB protein, as seen both by coimmunostaining (Fig. 1E, arrowheads) and by coimmunoprecipitation ( fig. S1 , B and C), indicating a direct interaction with PirB. This assay also confirms previously reported Nogo-66 binding to PirB ( fig. S2 ) (20) . In contrast, binding of Aβ42 oligomers was not evident in heterologous cells expressing mouse PirA1, mouse PirA4, or an isoform of rat PirB (23) ; all of these receptors are closely related to mouse PirB (Fig. 1, F and G, and fig. S3 ). This finding indicates that Aβ42 oligomers bind selectively to PirB. Oligo-Aβ42 binding to PirB expressed in HEK293 cells was saturable, with an apparent dissociation constant (K d ) of 180 nM monomer equivalent of total Aβ42 peptide ( Fig. 1 , H to J) (24) . An alkaline phosphatase assay gave a similar binding affinity (K d = 160 nM; fig. S4 ). In contrast, mono-Aβ42 exhibited no apparent binding affinity to PirB (Fig. 1, H 
to J).
Aβ42 oligomer binding to cultured cortical neurons from PirB −/− mice was diminished by about 50% relative to wild-type neurons, indicating that binding is PirB-dependent. The estimated K d for Aβ42 oligomers and neuronal PirB is 110 nM (Fig. 1K ), similar to that observed for PirB-expressing HEK293 cells (Fig. 1, I and J). We note that this binding is not completely abolished in the absence of PirB (Fig. 1K) , which suggests that additional binding sites for Aβ oligomers exist (6, 12, 25) . Together, these results suggest that PirB is a high-affinity receptor for Aβ oligomers.
The human homolog of murine PirB is leukocyte immunoglobulin (Ig)-like receptor B, which comprises five family members, LilrB1 to LilrB5 (19, 20) . To identify which of these orthologs functions analogously to PirB as a receptor for Aβ oligomers, we examined the three most related LilrB receptors, LilrB1, 2, and 3 (19, 20, 26, 27) , as well as a moderately related human killer immune receptor (Kir) (Fig. 2A) . Aβ42 oligomers robustly bound to LilrB2-expressing heterologous cells, but not to LilrB1-, LilrB3-, or Kir (3DL1)-expressing cells (Fig. 2B and fig. S5A ). Binding was saturable, with an apparent K d of 206 nM ( (Fig. 2, C and D) , which suggests selective binding with Aβ42 oligomers. LilrB2 proteins were detected in human brain specimens from both AD patients and non-AD adults (table S1), with no significant difference in levels (Fig. 2, E and F) ; however, downstream signaling was altered in AD (see below). These results suggest that LilrB2 is available as a receptor for Aβ oligomers in human brain. LilrB2 has also been identified as a human ortholog of PirB for other recently discovered nonimmune ligands: In vitro, PirB and LilrB2 act as functional receptors to inhibit axonal outgrowth on Nogo, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein substrates (20) ; in the hematopoetic system, angiopoietin-like proteins can also bind to PirB and LilrB2 to support stem cell and leukemia development (26) . These observations imply that mouse PirB may have diverse functions well beyond inhibitory signaling in the innate immune system and that LilrB2 may execute these roles in humans, particularly in the nervous system.
To determine the domains of PirB or LilrB2 responsible for Aβ oligomer binding, we made full-length or deletion mutants of PirB and LilrB2 (Fig. 2G ). Because Aβ oligomers appear to bind preferentially to dimeric PirB in heterologous cells ( fig. S6A ), soluble dimeric forms of PirB or LilrB2 extracellular domain were constructed using human IgG1-Fc ( fig. S6B ). In vitro binding to Aβ42 oligomers revealed that the two most N-terminal Ig domains (D1D2) of PirB and of LilrB2 are critical, whereas the PirB-D5D6 and LilrB2-D3D4 domains have minimal affinity (Fig. 2, G and H, and fig. S6C ) (28) . In this assay, PirB-Fc, LilrB2-Fc, and PirB(D1D2)-Fc proteins pulled down high-n Aβ42 oligomers (Fig. 2H) , recapitulating coimmunoprecipitation results (fig. S1B). PirB(D5D6)-Fc was used as a negative control and the oligomeric status of bound Aβ42 was confirmed using the oligomer-specific antibody OMAB (29) (Fig. 2H and fig. S6D ). These results suggest that PirB and LilrB2 are potent receptors for Aβ42 oligomers, and that their D1D2 domains are sufficient to mediate binding.
If PirB or LilrB2 mediates deleterious effects of Aβ on synaptic function, then deletion of PirB should mitigate them in cellular or animal models of AD. A cellular mechanism proposed to underlie memory impairment in AD is loss of hippocampal LTP resulting from the presence of soluble Aβ oligomers (2, 12) . To assess a direct contribution of PirB to this cellular correlate of AD pathology, we examined the effects of acute Aβ42 oligomer addition in wild-type and PirB −/− hippocampal slices; LTP at Schaffer collateral-CA1 synapses was measured (Fig. 3 , A to D). Because PirB has high affinity for Aβ oligomers (K d ≈ 110 to 180 nM; Fig. 1 and fig. S4 ), slices were treated with 200 nM total peptide of oligomerized Aβ42 or with vehicle control, and field excitatory postsynaptic potentials (fEPSPs) after theta burst stimulation (TBS) were recorded. Consistent with previous reports (12, 30) , Aβ42 oligomers abolished LTP in hippocampal slices from wild-type mice (vehicle, 134 ± 4% of baseline; Aβ42 oligomer, 94 ± 7% of baseline; Fig. 3 , A and C). In marked contrast, in PirB −/− slices, LTP remained intact even in the presence of Aβ42 oligomers (135 ± 5% of baseline; Fig. 3 , B and C); these effects were significantly different between wild-type and PirB −/− slices (Fig. 3D) . Application of vehicle control in PirB −/− slices did not alter the magnitude of LTP, which was similar to wild-type mice (125 ± 4% of baseline; Fig. 3 , B and C), consistent with previous observations of hippocampal LTP in PirB −/− mice (31) . These experiments demonstrate that the deleterious effects of Aβ oligomers on hippocampal LTP depend on PirB.
To assess whether PirB contributes in vivo to cognitive deficits, we crossed APP/PS1 transgenic (Tg) mice with PirB −/− mice to generate APP/PS1 littermates with (PirB +/− Tg) or without (PirB −/− Tg) PirB. First, recognition memory was examined using two tests: novel object recognition and novel place recognition (6, 32) . As expected (32) , impaired behaviors were observed in both tests in 9-month-old PirB +/− Tg mice; however, these learning and memory defects were not evident in mice lacking PirB (PirB −/− Tg) (Fig. 3, E  and F) . Together, these observations demonstrate that PirB contributes not only to Aβ-mediated loss of hippocampal LTP but also to defects in recognition memory that characterize older APP/PS1 mice and are symptoms of synaptic pathology in AD.
One of the earliest manifestations of pathology detected in APP/PS1 mice is impaired ODP (17) . We evaluated ODP during the developmental critical period (P22 to P32) by measuring the ability of one eye to expand its functional representation within visual cortex after removal of the other eye (Fig. 3G) . ODP was significantly diminished in APP/PS1 mice (PirB +/− Tg) (18%; Fig. 3, H and I) (17) . When we deleted PirB, the mice (PirB −/− Tg) showed no loss in ODP. In fact, PirB −/− Tg mice had ODP similar to that of PirB −/− mice and greater than that of PirB +/− mice (Fig. 3, H and I) , consistent with previous observations (18) and with the fact that PirB binds other ligands known to limit ODP in addition to Aβ (i.e., MHCI; Nogo; fig. S2 and S10) (18, 20, 33) .
Cellular mechanisms associated with ODP in visual cortex of juvenile APP/PS1 mice were also examined. LTD of synaptic responses in cortical layer 2/3 induced by low-frequency stimulation of layer 4 ( fig. S7A ) shares mechanisms with those that cause weakening of deprived-eye visually driven responses after monocular deprivation (34, 35) . The magnitude of LTD at L4 to L2/3 synapses in APP/PS1 mice is almost 3-fold greater than in nontransgenic littermates (fig. S7, B and C) . This excessive LTD in PirB +/− Tg slices is not evident in PirB −/− Tg slices ( fig. S7, B to D) . Collectively, these data show that PirB function is associated not only with synaptic and cognitive alterations induced in adult mice by Aβ but also with loss of plasticity during early development in visual cortex of APP/PS1 mice.
Next, to identify signaling mechanisms engaged by the association of oligomeric Aβ with either PirB or LilrB2, we compared downstream signaling pathways in APP/PS1 mice with or without PirB. From an unbiased proteomic screen, we identified the actin-depolymerizing factor cofilin, as well as the serine-threonine phosphatases PP2A and PP2B/calcineurin, as potential PirB interactors. These candidates have already been implicated in Aβ-dependent synaptic loss and are engaged after induction of hippocampal LTD or LTP (9, 14, (36) (37) (38) . In forebrains of APP/PS1 (PirB +/− Tg) mice, interactions of PirB with cofilin ( Fig. 4A) , as well as with protein phosphatases PP2A, B, or C ( fig. S8 ), were increased relative to nontransgenic littermates. In contrast, other PirB signaling pathways, including tyrosine phosphorylation of PirB and its association with SHP-2 (18, 39, 40), were not significantly changed (Fig. 4A, lanes 1 and 2) , nor were the levels of Aβ oligomers, including previously reported Aβ*56 (41) (56-kD high-n oligomers) ( fig. S9; lanes 2 and 4) . Together, these results suggest that the elevated interactions between PirB and cofilin or protein phosphatases in APP/PS1 mice are most likely to be caused by Aβ-PirB interactions.
PP2A and PP2B/calcineurin can activate cofilin by dephosphorylation at the Ser 3 residue (42, 43) , and the resulting actin filament disassembly appears to be crucial for Aβ oligomerinduced spine loss (9) . Indeed, levels of cofilin phosphorylation at Ser 3 normalized to total cofilin levels were reduced about 40% in juvenile (P30) APP/PS1 forebrains (Fig. 4, B and  D) , as well as in adult (P200) hippocampal synaptosomes (Fig. 4 , C and E), which were fully restored to normal levels by knocking out PirB (Fig. 4, B to E) . Cofilin activity could be decreased by LIM kinase (LIMK) 1/2, an upstream kinase that phosphorylates cofilin at Ser 3 ; no evident change was detected in LIMK1/2 activity in APP/PS1 mice with or without PirB (Fig. 4 , B to E), implying that PirB and LIMK signaling may regulate cofilin independently. Addition of Aβ42 oligomers to cultures of cortical neurons also consistently triggers cofilin activation (25% reduction in cofilin phosphorylation in wild-type neurons after 1 hour of treatment), as well as the loss of the postsynaptic protein PSD-95 (23% reduction after 24 hours of treatment) (Fig. 4, F and G) . These changes did not occur in cortical neuron cultures from PirB −/− mice. Levels of cofilin phosphorylation in human Alzheimer's brains were reduced by about 38% relative to those in non-AD control brains (Fig. 4, H and I) . In AD brains, elevated Tau phosphorylation was also observed (Fig. 4H) , consistent with AD diagnosis (table S1). Thus, the PirB receptor may act directly to link Aβ-induced synaptotoxicity and cofilin or protein phosphatase pathways (9): Aβ oligomer-PirB binding would recruit cofilin-signaling modules to facilitate actin depolymerization, resulting in synaptic loss (indicated by reduction of PSD-95), ultimately leading to altered synaptic plasticity and cognitive deficits in APP/PS1 mice ( fig. S10 ). In the cerebral cortex of Alzheimer's patients, LilrB2 could engage similar cofilin-mediated downstream mechanisms.
Our results show that murine PirB and its human ortholog LilrB2 act as receptors for oligomeric forms of Aβ42. Mice lacking PirB are immune to the damaging effects of Aβ in hippocampal LTP and recognition memory, as well as to alterations in cofilin signaling and PSD-95 synaptic loss. We suggest that interactions between Aβ oligomers and PirB generate not only synaptotoxicity in mouse models of AD but also early defects in developmental plasticity present in visual cortex (17) . The demonstration here that PirB −/− but not wildtype hippocampal slices are resistant to the acute effects of Aβ oligomers on LTP and that Aβ oligomers can alter cofilin signaling in wild-type but not PirB −/− cortical neurons in vitro, also argues that the rescue of AD phenotypes in PirB −/− Tg mice is via direct abrogation of PirB action, rather than indirect compensation or parallel signaling pathways. We also identify LilrB2 in human brain as an Aβ receptor that may contribute to synaptic loss and cognitive impairment in AD progression. Our results show that via PirB, Aβ oligomers can engage signaling pathways for neuronal actin organization that lead to synapse elimination. Therapies that selectively block LilrB2 function may be promising for treatment of AD even in the prodromal stage.
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